** Drugmaker Halozyme HALO.O sues Merck MRK.N over a subcutaneous version of cancer drug Keytruda, which HALO says uses a drug delivery technology patented by it
** Shares of HALO rise 1% to $59.03
** Last month, MRK, who is banking on the new version of Keytruda to protect it against a patent expiry in 2028, said that it plans to launch the drug on October 1
** The ultimate outcome of Halozyme's lawsuit should have no impact on the company's current or future licenses, revenues, or programs related to a newer drug delivery technology — TD Cowen
** "We see significant upside opportunity for Halozyme if they are awarded a royalty on Keytruda SC sales" — brokerage
** Including session's move, HALO stock up 23.6% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。